BPC-157 — 5mg
109.99€
Retatrutide — 10mg
The first triple-receptor agonist to activate GIP, GLP-1, and glucagon pathways simultaneously, with Phase 2 data showing 24.2% body weight reduction at 48 weeks.
289.99€
Netto 289.99€
- In Stock
- Evidence tier: Emerging
- Format: Lyophilized
- Purity: 99.3%
- Vial size: 10mg
Wyłącznie do badań laboratoryjnych. Nie do stosowania u ludzi ani zwierząt.
O produkcie Retatrutide
Retatrutide is the world's first GLP-1/GIP/glucagon triple receptor agonist to enter advanced clinical study. By engaging three distinct metabolic pathways simultaneously, it has generated unprecedented body composition data in published trials. It represents the next evolution beyond dual-agonist peptides like tirzepatide.
Retatrutide is the world's first GLP-1/GIP/glucagon triple receptor agonist to enter advanced clinical study. By engaging three distinct metabolic pathways simultaneously, it has generated unprecedented body composition data in published trials. It represents the next evolution beyond dual-agonist peptides like tirzepatide.
Retatrutide (LY3437943) is a single polypeptide conjugated to a fatty diacid moiety that activates GIP, GLP-1, and glucagon receptors. The triple agonism provides complementary metabolic benefits: GLP-1 reduces appetite and slows gastric emptying, GIP enhances insulin sensitivity and may promote fat storage efficiency, and glucagon receptor activation increases hepatic fat oxidation, energy expenditure, and thermogenesis. The glucagon component also significantly reduces hepatic steatosis, with Phase 2 data showing near-complete resolution of MASLD/MASH in some participants.
Poznanie mechanizmu: Well-characterized triple GIP/GLP-1/glucagon agonism
Tagi
Najważniejsze informacje
-
Ocena badań 7/10
Phase 2 completed, Phase 3 (TRIUMPH) ongoing opublikowanych badań w zbiorze danych
-
Poziom dowodów: Emerging
Emerging — Phase 2 complete with remarkable results (24.2% weight loss). Phase 3 (TRIUMPH program by Eli Lilly) underway. Not yet FDA-approved. Very promising but limited to one major Phase 2 trial published.
-
Dane u ludzi
Phase 2 RCT with ~300 participants (NEJM published)
Przechowywanie i obchodzenie się
Proszek liofilizowany: Room temp or refrigerated
Po rekonstytucji: Refrigerate, use within 30 days
Etapy rekonstytucji ze zbioru danych
- Clean. Remove flip-top cap and swab rubber stopper with alcohol.
- Draw water. Draw 2mL of bacteriostatic water into syringe.
- Inject water. Insert needle through stopper and slowly inject water down the side of the vial. Do not spray directly onto powder.
- Dissolve. Gently swirl (do not shake) until fully dissolved. Solution should be clear.
- Label. Label vial with date and concentration (5mg/mL). Refrigerate immediately.
- Dose. For 1mg dose: draw 0.2mL (20 units). For 2mg dose: draw 0.4mL (40 units). Inject subcutaneously once weekly.
Bezpieczeństwo i ograniczenia
Badany w kontekście: Weight loss, Metabolic syndrome, Prediabetes reversal, NAFLD/MASH, Body recomposition
Zgłaszany początek działania: 2-4 weeks for appetite effects; 8-12 weeks for significant weight loss
Zgłaszany czas trwania: Ongoing; dose escalation monthly from 0.5mg to 12mg
Relacje społeczności: Nausea more common than tirzepatide at higher doses (25%+). GI side effects dose-dependent. Limited community data due to early-stage availability. Clinical trial participants report dramatic weight loss and tolerable side effects.
For research and educational use only. Source values are reproduced from the current PeptidesEuro content dataset and are not medical advice.
Jakość i specyfikacja
Product details
- Kod produktu
- L-RETA-10
- Dostępność
- In Stock
- Evidence tier
- Emerging
- Format
- Lyophilized
- Purity
- 99.3%
- Vial size
- 10mg
Dane do rekonstytucji
- Woda bakteriostatyczna
- 2 mL
- Stężenie
- 5mg/mL when reconstituted with 2mL. 1mg dose = 0.2mL (20 units on insulin syringe).
- Strzykawka
- 29-31G insulin syringe
Parametry badawcze
- Ilość standardowa
- 1000 µg
- Ilość alternatywna
- 4000 µg
- Fiolka
- 10 mg
- Szacunek ze zbioru danych
- 1 vial lasts 10 weeks at 1mg/week
Raport laboratoryjny
- Laboratorium
- Janoshik Analytical
- Data badania
- 2026-03-01
- Dokument
- PDF nie jest dołączony
Zobacz badania
-
Czytaj badanie: Triple hormone receptor agonist retatrutide for MASLD (otwiera się w nowej karcie)
Triple hormone receptor agonist retatrutide for MASLD
Significant liver fat reduction; potential MASH resolution in Phase 2 participants
-
Czytaj badanie: Triple-Hormone-Receptor Agonist Retatrutide for Obesity — Phase 2 Trial (otwiera się w nowej karcie)
Triple-Hormone-Receptor Agonist Retatrutide for Obesity — Phase 2 Trial
Up to 24.2% weight loss at 48 weeks; 72% of prediabetic participants reverted to normoglycemia
-
Czytaj badanie: Retatrutide — A Game Changer in Obesity Pharmacotherapy (otwiera się w nowej karcie)
Retatrutide — A Game Changer in Obesity Pharmacotherapy
Potent activation of all three receptors (GIP/GLP-1/glucagon); significant weight reduction and metabolic improvements
Badania podano w celach informacyjnych. Większość przeprowadzono na modelach zwierzęcych lub komórkowych; ich wyniki nie dowodzą bezpieczeństwa ani działania u ludzi.
Dalsza lektura
Community evidence
- Source window English Reddit Updated 13 Aug 2026 · 2-year window
- Coverage confidence Low Confidence in the available community sample
- Distribution Pending Not enough data for a distribution.
Selected reports
-
1 year agor/Testosterone · Post
my face most notably returned to pre-trt levels of water retention literally in about 2 weeks
-
3 months agor/RetatrutideWomen · Post
My dosing was: 500 mcg for 5 weeks 750 mcg for 5 weeks 1 mg for 1 week I stopped cold turkey 3 weeks ago with no tapering.Towards the end of the cycle and for a while after stopping, I felt really rough. … Hey everyone,Wanted to share my experience with Retatrutide (reta) in cas…
Based on 2 qualifying reports from 2 threads. 39 candidates excluded as duplicates, promotion, deleted content, or lacking concrete personal experience. Reddit self-reports are not medical evidence or proof of causation.
Pytania o Retatrutide
Pytania i odpowiedzi zapisane dla tego produktu.
Not yet. Phase 2 is complete with remarkable results. Phase 3 (TRIUMPH program by Eli Lilly) is currently underway. It is the most advanced triple agonist candidate in development.
Phase 2 data published in Nature Medicine showed significant liver fat reduction, with near-complete MASLD/MASH resolution in some participants. The glucagon receptor component specifically drives hepatic fat oxidation — an effect unique to triple agonists.
Retatrutide is a triple agonist (GIP + GLP-1 + glucagon) while tirzepatide is a dual agonist (GIP + GLP-1). The added glucagon receptor activation drives hepatic fat oxidation and energy expenditure. Phase 2 data showed up to 24.2% weight loss vs tirzepatide's 22.5% in separate trials.
Opinie
Ten produkt nie ma jeszcze opinii.
Powiązane produkty
-
-
MOTS-c — 10mg
189.99€
-
Tirzepatide — 10mg
189.99€
-
Tesamorelin — 10mg
279.99€
Jak działa zamawianie
Dane produktu, źródła i zamówienie pozostają ze sobą powiązane.
-
Wybierz związek
Wybierz związek i rozmiar fiolki w katalogu.
-
Sprawdź informacje o produkcie
Otwórz szczegóły produktu i powiązane badania.
-
Zachowaj źródła
Zapisz źródła do swojej dokumentacji.
Dlaczego zamawiać w PeptidesEuro
Profile związków
Struktura, dostępne rozmiary i uwagi dotyczące obchodzenia się w jednym miejscu.
Źródła badań
Strony produktów prowadzą do badań dotyczących każdego związku.
Jedna historia zamówień
Zamówienia i ich szczegóły pozostają na Twoim koncie.
Przejrzyste dane produktu
Cena, dostępność i podatek przy każdym produkcie.
PeptidesEuro is a research materials supplier operated by Pepticore LLC. We provide high-purity peptides and research compounds for in-vitro laboratory and scientific research purposes. All products are sold strictly for research use only and are not intended for human or animal consumption.
No. All products sold through meimx.com are intended strictly for in-vitro laboratory and scientific research purposes only. They are not intended for human or animal consumption, injection, ingestion, inhalation, or any form of administration to living organisms. By purchasing from PeptidesEuro, you acknowledge and agree to these terms as outlined in our Terms of Service.
No. Our products have not been evaluated, approved, or authorized by the U.S. Food and Drug Administration (FDA) or any other regulatory body. They are not intended to diagnose, treat, cure, mitigate, or prevent any disease or medical condition. PeptidesEuro is not a compounding pharmacy or outsourcing facility as defined under Sections 503A or 503B of the Federal Food, Drug, and Cosmetic Act.
No. PeptidesEuro does not provide medical advice, treatment recommendations, or dosing instructions. Any information on our website, including product descriptions and referenced research, is provided for educational and informational purposes only. If you have medical questions, please consult a licensed healthcare provider.
Research Use Only means that our products are sold exclusively as reference standards and research materials for use in laboratory and scientific research settings. Purchasers agree to use all products solely for legitimate research purposes in compliance with all applicable laws and regulations.
Gotowy, by zamówić Retatrutide?
Przeglądaj katalog albo odpowiedz na jedno pytanie w wyszukiwarce produktów.